News

Friday, 08 November 2019

Visit us at DDL2019 Conference at stand 222!


From 11th to 13th December 2019 the Drug Delivery to the Lungs (DDL) Conference will once again take place in Edinburgh.

Read more


Tuesday, 10 September 2019

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis


News published by Santhera Pharmaceuticals concerning POL6014 in cystic fibrosis, administered with an optimised investigational eFlow® Technology nebuliser.

Read more


Thursday, 25 July 2019

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma


News published by Zambon Pharma concerning the acquisition of biopharmaceutical company Breath Therapeutics

Read more

News published by Gimv concerning the sale of biopharmaceutical company Breath Therapeutics

Read more

News published by Sofinnova Partners concerning the sale of biopharmaceutical company Breath Therapeutics

Read more


Monday, 20 May 2019

Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis


News published by Respivant Sciences concerning RVT-1601, administered with an optimized investigational eFlow® Technology nebuliser.

Read more


Monday, 20 May 2019

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimised eFlow® Technology nebuliser.

Read more


Thursday, 08 May 2019

Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein


News published by Savara Pharmaceuticals concerning Molgradex (GM-CSF) in aPAP, administered with an optimized investigational eFlow® Technology nebuliser.

Read more


Wednesday, 01 May 2019

Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019


News published by Sunovion Pharmaceuticals Inc. presenting data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.

Read more


Tuesday, 26 March 2019

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.


News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow® Technology nebuliser.

Read more


Tuesday, 02 October 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).


ARIKAYCE® is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

Read more


Thursday, 07 December 2017

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)


LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!
eFlow-partneringpari.com